FDC at 52-wk high as Goa plant gets GMP certificate from UK drug regulator

In the past two months, FDC has outperformed the market by surging 25 per cent, after reporting a healthy September quarter earnings (Q2FY20)

Shares of FDC hit a 52-week high of Rs 222 on the BSE after rallying 5 per cent in intra-day trade on Friday in an otherwise range-bound market after the drug company received good manufacturing practice (GMP) certificate from UK drug regulator for its Goa plant. The stock surpassed its previous high of Rs 220, recorded on May 27, 2019.

“The Company has received GMP certificate and it continues with its approved status from UK MHRA (Medicines and Healthcare Products Regulatory Agency), for two of its Oral solid Dosage form facilities situated at L-56/57 and L-121 in Verna, Goa,”